Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ramucirumab in pediatric refractory solid tumors
NCT02564198Phase 1Completed
- Sponsor
- Eli Lilly and Company
- Start
- Dec 2015
- Primary completion
- Jul 2019
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of ramucirumab in solid tumor and central nervous system tumor (2 arms), sponsored by Eli Lilly and Company. Primary endpoints: Dose Limiting Toxicities, Minimum Concentration of Ramucirumab and 1 more. Started Dec 2015; status: completed.
02
Drugs
ramucirumab
03
Conditions
solid tumorcentral nervous system tumor
Beyond the preview
Go deeper on NCT02564198.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02564198.